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INTRODUCTION 
 
The global population of people older than 65 years is estimated to rise dramatically 
due to advances in average life expectancy (1). A massive increase in the numbers of elderly 
persons; from 600 million at present to nearly 2 billion in 2050, is expected to happen worldwide 
and, approximately, 25 % of the population in developed countries will be older than 65 (1). 
To date, the ageing population presents a challenge for the public healthcare system 
since the elderly suffer from more frequent and severe infections compare to their younger 
counterparts (2). In addition, poor outcomes from infections tend to be experienced by aged 
people in comparison to the younger population. Influenza, particularly, is an example of a 
common infection which causes annual epidemics, and in the elderly, is associated with 
increased morbidity. In fact, one of the ten major causes of death in the elderly is influenza (2). 
One of the main reasons for the increase of infections observed in the elderly is 
believed to be a gradual deterioration of the immune system that occur with ageing which leads 
to a decline in the response to infection by both the innate and adaptive immune systems, 
namely immunosenescence (2,3). Immunosenescence was introduced for the first time by Dr. 
Roy Walford (4). 
Basically, since the immune response in the elderly declines and the outcome of infect-
ion is often poor, prevention of infection becomes critically important (3). Vaccination against 
important infectious pathogens such as influenza, could provide a sufficient protection in the 
elderly and in this case is recommended by the World Health Organization (5). Unfortunately, 
immunosenescence not only impairs the ability of the immune system to fend off infection but 
also its capacity to respond to immunisation, as shown by the reduced efficacy of annual 
influenza vaccination in the elderly, with an efficacy of 17-53% in the elderly compare to 70-90% 
in healthy adults (6). 
Despite considerable progress in influenza vaccine development and our understanding 
in immunosenescence mechanisms, we still do not have a clear understanding regarding the 
impact of immunosenescence on the effectiveness of influenza vaccination in the elderly. It is 
important to identify this issue since several studies have reported the effectiveness of influenza 
vaccination in the elderly during seasonal outbreak (7,8,9,10,11) while other studies present 
contradictory results (12,13,14). Further elucidation of the relationship between immunosene-
scence and infuenza vaccination efficacy would reveal the way to improve immune response of 
the aged people and therefore, improve their quality of life during influenza outbreak. In this 
review, we will discuss on recent advances in innate and adaptive immune response, especially 
in mucosal immune system, during ageing and this knowledge should eventually lead to the 
development of more effective influenza vaccines for the elderly   
 
 
 
CHANGES IN THE INNATE IMMUNITY DUE TO 
AGEING 
Innate immunity is the first line of defense 
in immune system, comprises the cells and 
mechanisms that protect the host from infection by 
pathogens, in a non-specific manner (15). The 
innate immune system includes several cellular 
components such as monocytes/macrophages, 
natural killer (NK) cells, natural killer T (NKT) cells, 
dendritic cells (DCs), neutrophils, eosinophils, and 
basophils, and by the elaboration of proinflammat-
ory cytokines, type I interferons (IFNs) and other 
soluble factors which provide protection against 
bacterial and viral infections (16,17).  
The innate immune system identifies pa-
thogens via pattern-recognition receptors (PRRs), 
such as toll-like receptors (TLR), which triggering a 
variety of signalling pathways subsequent to the 
recognition of specific molecular patterns that pre-
sent on the surface of the pathogens  (16). PRRs 
have several characteristics. First, PRRs could 
recognise microbial components, known as 
pathogen-associated molecular patterns (PAMPs) 
8   Majalah Farmasi dan Farmakologi, Vol. 16, No. 1 – Maret 2012, hlm. 7 – 12  
that are essential for the survival of the micro-
organisms. Different PRRs will respond to specific 
PAMPs, demonstrate distinct expression patterns, 
activate specific signaling pathways, and lead to 
distinct antipathogen responses. Second, PRRs 
are expressed constitutively in the host and will 
detect the pathogens despite of their life-cycle 
stage. Third, PRRs are germline encoded, non-
clonal, expressed on all cells of a given type, and 
independent from immunological memory (15).  
However, recent studies evaluating the effects of 
ageing on the innate immune system reveal that 
the function of innate cellular components declines 
with age, which might suggest an explanation for 
the increased frequency of bacterial and viral 
infections among the elderly (6,16,18,19). 
A study in 1994 showed that phagocytic 
activity did not affected by ageing (20). However, 
recent evidence suggests that the phagocytic ac-
tivity and the production of superoxide anion in 
macrophages had been declined in the elderly (21) 
as well as their ability to present the antigens to the 
T cells (22). Several studies had demonstrated the 
increase of the number of NK cells in the elderly 
and are associated with an increase in the CD56
dim
 
population of NK cells (23,24,25,26). Nevertheless, 
overwhelming evidence indicates depressed NK 
function such as impaired NK cell cytotoxicity and 
decreased production of cytokines and che-
mokines by activated NK cells are associated with 
age (21). In addition, evidence indicates the de-
crease of DCs’ ability of aged people to stimulate 
T-cell proliferation, diminished expression of co-
stimulatory molecules, and inadequate production 
of interleukin (IL)-12 has been reported (22).  
CHANGES IN THE ADAPTIVE IMMUNITY DUE 
TO AGEING 
All immune cells arise from the haemato-
poietic stem cells (HSC) in the bone marrow (27). 
A study by Aw et al. (2007) shows that a reduced 
ability of HSC in the production of B-cell precursors 
is possibly due to an intrinsic and micro-environ-
mental defects at bone marrow level. Simultane-
ously, intrinsic B-cell defects may occur in the 
periphery along with age, including low immuno-
globulin titer and abnormal B-cell receptor signal-
ing (21). Moreover, even though proliferative capa-
city of B-cells has been diminished, an increased 
production of autoantibodies may result from in-
adequate inhibition by suppressor T-cells (28). 
Immunosenescence also affected T-cell’s 
function (28). Maue et al. (2009) have demonstrat-
ed the relationship between immunosenescence 
and significant defects in CD4+ and CD8+ T-cell 
responses (29). Theoretically, increasing age is 
predicted to be associated with a well-functioning 
memory T-cell population that can respond to pre-
viously encountered pathogens (2). In other words, 
we should be able to cope with more infections as 
we get older. However, a decline production of 
cytokines such as interferon gamma (IFN-γ), tumor 
necrosis factor alpha (TNF-α), IL-1, and IL-6 by T-
helper (Th)-1 (30), drastic contraction in CD4+ T-
cell diversity (31), and decreased antigen-
recognition repertoire of CD8+ T-cells among the 
elderly (32) have been reported in the elderly. 
Furthermore, in addition to the vulnerability to new 
pathogens, the elderly often have difficulties in 
dealing with pathogens which they have previously 
encountered, including the annual return of 
influenza (33). 
THE IMPACT OF MUCOSAL IMMUNOSENE-
SCENCE ON INFLUENZA INFECTION  
Older individuals are much more suscept-
ible to infections (34) including the fact that the 
severity and mortality caused by the pathogens 
invading mucosal surfaces such as influenza virus 
are significantly increased in humans of advanced 
age (35). 
To date, there are three types of influenza 
viruses are known to be responsible for influenza 
related diseases: type A, B, and C (36). However, 
Influenza A virus is the most virulent among influ-
enza viruses and is classified into several subtypes 
based on the antigenic properties of two viral 
antigens, Hemagglutinin (HA) and Neuraminidase 
(NA), which are attached on the surface of the 
virus (36). HA plays an important role in determin-
ing the host specificity and the mechanism of viral 
entry into the host cells through an interaction with 
sialic acid (SA) receptor in the upper respiratory 
tract of the host (37). Therefore, Chen et al. (2009) 
suggested that hemagglutination inhibition (HAI) 
antibody is the most accepted immunological 
protection against influenza A viruses (1). 
According to Harriman et al. (1999), effect-
ive protection can be provided by pathogen-
specific systemic IgG without mucosal IgA res-
ponses (38). However, pathogen-specific SIgA res-
ponses are a necessary component for providing 
the first-line barrier of effective immunity against 
these respiratory pathogens at their entry site in 
the elderly (39). Recently, an important role of 
influenza HA-specific SIgA responses in protecting 
the body against the influenza virus in the upper 
respiratory tract has been documented. Further-
more, it is also providing a cross-protection against 
infection caused by a variant of influenza virus 
within the same subtype when compared with 
those of serum IgA Antibodies (39).  
Up to now, only few studies in the effect of 
ageing on the upper respiratory tract immune 
system have been documented (39). Hagiwara et 
al. (2003) has reported a decrease frequency of 
naïve CD4+, CD45RB+ T-cells in Nasopharyngeal-
associated lymphoreticular tissues (NALT) of 
ageing mice (40). However, the size and the total 
lymphocyte count in the NALT of mice increases 
approximately five- to ninefold during the ageing 
process through the first year (39). It is suggested 
that two years old experimental mice could be 
considered equivalent to aged-humans (40,41,42). 
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Nevertheless, the differences of the nasal cavity 
between mice and humans should be considered 
in any future development of nasal vaccines (39).  
IMMUNOSENESCENCE AND INFLUENZA VAC-
CINATION EFFICACY IN THE ELDERLY 
Vaccination is critically important in order 
to prevent infection and to protect people from 
disease (43). However, the efficacy of a vaccine 
depends on the quality of the immune responses; 
therefore, immunocompromised persons such as 
infants and older individuals are more likely to be 
insufficiently protected (44).  
Regarding disastrous outbreak of “Spanish 
flu” in 1918, annual vaccination against influenza 
has been recommended to everybody especially 
older people aged > 65 years (5,45). Several studi-
es have suggested the benefit of influenza vaccin-
ation during seasonal outbreak especially in the 
elderly (7,8,11,46,47,48,49). However, Chen et al. 
(2006) identified some of the studies have been 
criticized in the methodological problems including 
inadequate consideration of potential bias; variab-
ility in the serological match between the vaccine 
virus strains and the circulating influenza strains 
and the use of outcome measures with low sensi-
tivity (influenza-like illness rather than laboratory 
confirmed influenza) (1). In addition, Goodwin et al. 
(2006) reported that antibody responses following 
influenza vaccination are lower in elderly persons 
than in young adults (6). Furthermore, diminished 
influenza-vaccine related protection against influ-
enza illness is frequently observed in the elderly 
and is considered, in part, due to ineffectiveness of 
an ageing immune system (28). 
One of the hallmarks of the immunosene-
scence in aged people is a decline in the antibody 
production which will impair the status of humoral 
responses. It is, unfortunately, believed that this 
event has a negative impact on the effectiveness 
of many current vaccines, including influenza 
vaccines, since the goal of the administration of the 
vaccines into the body is to improve the immune 
system by increasing the humoral responses, 
including antibody production (28,29). Declining 
immune function due to ageing and resultant im-
pairment on the innate immune response could 
reduce the effectiveness of the vaccination pro-
grams due to the decrease of the antigen uptake at 
the site of injection, resulting from a reduced 
phagocytosis (44). Improved antigen delivery sys-
tems (e.g. liposomes and virosomes), immuno-
stimulatory adjuvants (such as saponins, adjuvants 
targeting TLRs), or the administration of recom-
binant cytokines might help overcome these limit-
ations (43). 
Since the immunosenescence phenomena 
occurs earlier in the mucosa than in the systemic 
compartments, the development of mucosal vac-
cines against influenza viruses for the elderly 
(especially A-type) offers both promises and signi-
ficant challenges. For instance, gaps in the mucos-
al immunosenescence studies between mouse 
and human subjects should be revealed, as well as 
the development of mucosal modulators including 
novel mucosal adjuvants that can overcome mu-
cosal immunosenescence in the elderly. Further-
more, differences in the immune response of the 
elderly populations from various countries are 
influenced by commensal flora, nutritional uptake, 
genetic background, life style, and so forth (39).  
CONCLUSION  
In the elderly, many changes happened in 
both the innate and the adaptive immune respons-
es. These changes are generally viewed as the 
deterioration of immunity, leading to the use of the 
term immunosenescence, which is might respons-
ible for the increased susceptibility of elderly to 
infectious diseases such as influenza. Hence, a 
better understanding of the immunosenescence 
and its effects on the influenza vaccination in the 
elderly would reveal new strategies on the influ-
enza vaccine development.    
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